Dicerna Pharmaceuticals, Inc. (DRNA): Price and Financial Metrics

Dicerna Pharmaceuticals, Inc. (DRNA): $36.90

-0.04 (-0.11%)

POWR Rating

Component Grades













Add DRNA to Watchlist
Sign Up

Industry: Biotech


of 502

in industry


  • Value is the dimension where DRNA ranks best; there it ranks ahead of 74.64% of US stocks.
  • DRNA's strongest trending metric is Growth; it's been moving down over the last 31 weeks.
  • DRNA's current lowest rank is in the Momentum metric (where it is better than 5.04% of US stocks).

DRNA Stock Summary

  • With a price/sales ratio of 16.13, Dicerna Pharmaceuticals Inc has a higher such ratio than 87.75% of stocks in our set.
  • With a year-over-year growth in debt of 118.05%, Dicerna Pharmaceuticals Inc's debt growth rate surpasses 91.72% of about US stocks.
  • As for revenue growth, note that DRNA's revenue has grown 224.45% over the past 12 months; that beats the revenue growth of 96.89% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Dicerna Pharmaceuticals Inc, a group of peers worth examining would be XNCR, XENE, MPX, RGNX, and PLAN.
  • Visit DRNA's SEC page to see the company's official filings. To visit the company's web site, go to www.dicerna.com.

DRNA Valuation Summary

  • In comparison to the median Healthcare stock, DRNA's price/sales ratio is 350% higher, now standing at 16.2.
  • Over the past 91 months, DRNA's EV/EBIT ratio has gone up 17.7.
  • Over the past 91 months, DRNA's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for DRNA.

Stock Date P/S P/B P/E EV/EBIT
DRNA 2021-05-13 10.9 15.3 -16.1 -15.2
DRNA 2020-05-13 30.3 9.3 -14.2 -12.3
DRNA 2019-09-16 82.5 6.1 -11.2 -10.1
DRNA 2018-10-16 142.4 11.0 -7.6 -8.3
DRNA 2017-08-14 102.1 5.2 -1.0 -0.5
DRNA 2016-02-19 624.5 1.1 -1.9 -1.0

DRNA Growth Metrics

  • Its year over year net income to common stockholders growth rate is now at -2.93%.
  • Its year over year cash and equivalents growth rate is now at -35.18%.
  • Its year over year net cashflow from operations growth rate is now at -169.6%.
DRNA's revenue has moved up $153,978,000 over the prior 15 months.

The table below shows DRNA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-03-31 177.882 -172.672 -120.22
2020-12-31 164.307 175.112 -112.747
2020-09-30 130.431 207.491 -115.831
2020-06-30 89.591 232.5 -124.772
2020-03-31 54.825 248.105 -116.797
2019-12-31 23.904 -0.692 -120.459

DRNA Price Target

For more insight on analysts targets of DRNA, see our DRNA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $42.00 Average Broker Recommendation 1.36 (Strong Buy)

DRNA Stock Price Chart Interactive Chart >

Price chart for DRNA

DRNA Price/Volume Stats

Current price $36.90 52-week high $40.14
Prev. close $36.94 52-week low $16.50
Day low $35.89 Volume 499,400
Day high $37.29 Avg. volume 762,803
50-day MA $35.91 Dividend yield N/A
200-day MA $27.77 Market Cap 2.84B

Dicerna Pharmaceuticals, Inc. (DRNA) Company Bio

Dicerna Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company is using its proprietary RNA interference technology platform to build a broad pipeline in these therapeutic areas. The company was founded in 2006 and is based in Cambridge, Massachusetts.

DRNA Latest News Stream

Event/Time News Detail
Loading, please wait...

DRNA Latest Social Stream

Loading social stream, please wait...

View Full DRNA Social Stream

Latest DRNA News From Around the Web

Below are the latest news stories about Dicerna Pharmaceuticals Inc that investors may wish to consider to help them evaluate DRNA as an investment opportunity.

Dicerna to Report Second Quarter 2021 Financial Results on Aug. 9, 2021

LEXINGTON, Mass., August 02, 2021--Dicerna announced that the Company will release its second quarter 2021 financial results before market open on Monday, Aug. 9, 2021.

Yahoo | August 2, 2021

Dicerna Pharmaceuticals (DRNA) to Report Q2 Results: Wall Street Expects Earnings Growth

Dicerna Pharmaceuticals (DRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 29, 2021

Dicerna Announces FDA Clearance of Investigational New Drug (IND) Application for DCR-AUD for the Treatment of Alcohol Use Disorder

LEXINGTON, Mass., July 29, 2021--Dicerna announced the FDA clearance of its IND application for DCR-AUD for the treatment of alcohol use disorder.

Yahoo | July 29, 2021

Dicerna slips from peak after data for liver disease trial; RBC analyst shrugs off impact

alexsl/iStock via Getty Images Having closed at the highest level since early 2014 on Tuesday, Dicerna Pharmaceuticals (DRNA) dropped ~3.8% today after the company announced interim data for belcesiran in Alpha-1 antitrypsin deficiency-associated liver disease ((AATLD)). Despite the “numerically inferior” mean maximum serum AAT reductions in the Phase 1 trial, RBC analyst Luca Issi...

Seeking Alpha | July 21, 2021

Dicerna Announces Interim Results From Phase 1 Trial of Belcesiran for Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

LEXINGTON, Mass., July 21, 2021--Dicerna announced interim results from its Phase 1 trial of belcesiran for treatment of alpha-1 antitrypsin deficiency-associated liver disease.

Yahoo | July 21, 2021

Read More 'DRNA' Stories Here

DRNA Price Returns

1-mo N/A
3-mo 38.36%
6-mo 34.62%
1-year 64.59%
3-year 181.68%
5-year 985.29%
YTD 67.50%
2020 0.00%
2019 106.08%
2018 18.38%
2017 213.54%
2016 -75.74%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8089 seconds.